In like manner, Wang et al. [116] demonstrated the effectiveness of combining decitabine with camrelizumab (a PD-1 inhibitor) in Hodgkin lymphoma patients who previously failed treatment with PD-1 inhibitors. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.